Trial Profile

An early access program of AKANTIOR (polihexanide) for the treatment of acanthamoeba keratitis

Status: Planning

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 13 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Polihexanide (Primary)
Indications Acanthamoeba infections
Focus Expanded access; Therapeutic Use

Most Recent Events

13 Jun 2022 New trial record
07 Jun 2022 According to a SIFI media release, the company has launched this program in June 2022. The Company has partnered with Durbin, a part of Uniphar Group's Product Access Division and a leading specialist in the international distribution of specialized pharmaceuticals, to manage this Polihexanide Access Program.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com